Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Company Overview

Syros Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines that regulate gene control, with the goal of addressing diseases driven by abnormal gene expression. The company used genomic and molecular biology research to identify patient populations most likely to benefit from targeted therapies.

Its leading investigational product was tamibarotene, an oral selective retinoic acid receptor alpha agonist studied for genetically defined forms of acute myeloid leukemia and myelodysplastic syndrome. Syros also evaluated additional targeted oncology programs, including the investigational CDK7 inhibitor SY-5609, before discontinuing its development.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Syros conducted drug discovery and clinical-development activities for patients with serious diseases, primarily through research and clinical collaborations. The company’s programs were investigational and had not established approved commercial products based on the information available.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 1,978 shs
• Average Volume: 16,160 shs
• Market Capitalization: $10.73 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 10/31/2024
• Today: 10/16/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SYRS
• CIK: 1556263
• Web: www.syros.com
• Phone: (617) 744-1340
• Fax: N/A
• Employees: 120
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$164.57 million
• Net Margins: N/A
• Pretax Margin: -25,275.20%
• Return on Equity: -3,369.56%
• Return on Assets: -97.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $386 thousand
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 26,832,000
• Free Float: 23,542,000
• Market Cap: $10.73 thousand
• Optionable: No Data
• Beta: 1.31